Getting a shot of an experimental peptide drug TP508 within 24 hours after exposure to potentially-lethal level of radiation can significantly increase survival rate and delayed mortality, according to a pre-clinical study published in the journal Laboratory Investigation.
The investigation drug is believed to counteract the physical hazards of radiation and radiation-induced injury to the gastrointestinal system. The investigational peptide was originally developed to aid repair of bone, skin and muscle tissues.
According to the study guide, Dr. Carla Kantara, The University of Texas Medical Branch, the peptide may be an effective intervention to increase survival in a nuclear emergency and lethal level exposure.
The researchers found that the drug was effective in healing diabetic foot ulcers and wrist fractures without causing serious side effects.